Volume | 1,763,310 |
|
|||||
News | - | ||||||
Day High | 1.63 | Low High |
|||||
Day Low | 1.56 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.62 | 1.56 | 1.63 | 1.60 | 1.61 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,538 | 1,763,310 | $ 1.59 | $ 2,810,276 | - | 0.92 - 3.789 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:50 | formt | 200 | $ 1.59 | USD |
Lexicon Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
391.88M | 244.92M | - | 1.2M | -177.12M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lexicon Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.72 | 1.8575 | 1.56 | 1.64 | 3,980,090 | -0.13 | -7.56% |
1 Month | 2.00 | 2.47 | 1.56 | 1.94 | 3,189,126 | -0.41 | -20.50% |
3 Months | 1.80 | 3.73 | 1.56 | 2.46 | 4,720,987 | -0.21 | -11.67% |
6 Months | 1.11 | 3.73 | 0.92 | 2.03 | 3,607,155 | 0.48 | 43.24% |
1 Year | 2.53 | 3.789 | 0.92 | 2.05 | 2,975,557 | -0.94 | -37.15% |
3 Years | 4.97 | 6.3299 | 0.92 | 2.48 | 1,504,560 | -3.38 | -68.01% |
5 Years | 5.86 | 9.65 | 0.92 | 3.23 | 1,922,287 | -4.27 | -72.87% |
Lexicon Pharmaceuticals Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |